Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Trazodone
|
| gptkbp:activities |
serotonin antagonist and reuptake inhibitor
|
| gptkbp:approves |
gptkb:legislation
gptkb:1981 gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:brand |
gptkb:Desyrel
gptkb:Oleptro |
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
depression treatment
anxiety treatment chronic pain treatment insomnia treatment post-traumatic stress disorder treatment |
| gptkbp:code |
N06 A X05
|
| gptkbp:contraindication |
MAO inhibitors
hypersensitivity to trazodone |
| gptkbp:dosage_form |
150-600 mg/day
|
| gptkbp:financial_products |
D B00532
|
| gptkbp:formulation |
gptkb:tablet
extended-release tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Trazorel
|
| gptkbp:ingredients |
C19 H22 Cl N5 O
|
| gptkbp:interacts_with |
gptkb:beer
CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_used_for |
gptkb:historical_event
|
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
5 to 9 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
various pharmaceutical companies
|
| gptkbp:metabolism |
liver
|
| gptkbp:previous_name |
gptkb:trazodone
2-[3-(4-chlorophenyl)-1-methyl-2-piperazinyl]ethyl-1,2,3,4-tetrahydrocarbazole-1,2-dione |
| gptkbp:related_to |
sleep disorders
anxiety disorders bipolar disorder suicidal thoughts obsessive-compulsive disorder serotonin syndrome serotonin reuptake inhibitors chronic pain syndromes antidepressant discontinuation syndrome |
| gptkbp:side_effect |
dizziness
nausea drowsiness constipation dry mouth |
| gptkbp:type_of |
623-96-7
|